Intuitive Surgical VP executes $464,761 in stock sales

Fredrik Widman, Vice President and Corporate Controller at Intuitive Surgical Inc . (NASDAQ:ISRG), a medical technology company with a market capitalization of $202 billion, recently made significant transactions involving the company’s stock. According to a recent SEC filing, Widman sold 810 shares of Intuitive Surgical common stock on March 3, 2025, at a price of $573.78 per share, totaling approximately $464,761. This sale was conducted under a trading plan compliant with SEC Rule 10b5-1. InvestingPro data shows the stock has delivered an impressive 42% return over the past year.

Additionally, on February 28, 2025, Widman acquired 468 shares of common stock through the exercise of Restricted Stock Units (RSUs), which were part of his compensation package. The RSUs were converted into common stock without any purchase cost, as per the company’s vesting schedule.

Furthermore, on the same day, Widman disposed of 233 shares to cover tax withholding obligations related to the RSU conversion, at a price of $563.77 per share, totaling $131,358. Following these transactions, Widman holds 473 shares of Intuitive Surgical common stock directly.

In other recent news, Intuitive Surgical reported a strong performance in the fourth quarter of 2024, exceeding expectations with a 10% revenue beat and a 24% earnings per share (EPS) beat. RBC Capital Markets maintained an Outperform rating with a $641 price target, emphasizing the company’s 18% year-over-year procedure volume growth. Piper Sandler also raised its price target to $670, citing the company’s ability to surpass consensus expectations and projecting a 14.6% revenue growth for 2025. Despite some concerns about market saturation and pricing, Oppenheimer maintained a Perform rating after Intuitive Surgical’s GAAP EPS of $1.88 exceeded both their estimate and the consensus. Bernstein maintained an Outperform rating with a $700 target, highlighting a 38% year-over-year EPS increase and strong margin performance. Truist Securities increased its price target to $666, maintaining a Buy rating and expressing optimism about Intuitive Surgical’s growth trajectory. The anticipated mid-2025 full launch of the da Vinci (EPA:SGEF) 5 system is a focal point for many analysts, seen as a driver for future growth.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.